We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Particle Size Not Cholesterol Determines Capacity of HDL to Reduce CVD

By LabMedica International staff writers
Posted on 16 Aug 2016
Results of a recent study suggested that the number and size of high-density lipoprotein (HDL) particles in the blood were better indicators of cardiovascular disease (CVD) risk than was the classical measurement of HDL-cholesterol.

To try to explain why treatments to elevate plasma high-density lipoprotein cholesterol (HDL-C) fail to reduce CVD risk, investigators at the Hebrew University of Jerusalem (Israel) recruited a study population comprising 504 Jerusalem residents (274 Arabs and 230 Jews). More...
The participants' HDL was measured and classified by NMR spectroscopy, and calcification in their coronary arteries (CAC), reflecting the overall burden of coronary atherosclerosis, was determined by multidetector helical CT-scanning.

Results revealed that HDL-C was not protectively associated with CAC, but that HDL particle number (HDL-P) was strongly protectively associated with CAC. Small and medium-sized HDL (MS-HDL-P) and HDL-P accounted for the protective effects of HDL-P. Large HDL-P and average HDL-P size were not significantly associated with CAC. Therefore, MS-HDL-P and HDL-P were better risk markers for CAC than the traditional HDL-C.

"Our findings indicate that HDL-P and MS-HDL-P are better independent markers of coronary artery disease, as reflected by coronary artery calcification, than HDL-C, at least in this bi-ethnic population of Israelis and Palestinians," said first author Dr. Chobufo Ditah, (from Cameroon) a master of public health student at the Hebrew University of Jerusalem. "These findings support previous reports, based on studies in other population groups, suggesting that small dense HDL particles are protectively associated with risk of coronary heart disease. The consistency of this finding in a new population of urban Arabs and Jews, using different disease outcomes and different separation methods, add more strength to those findings."

"With a better understanding of HDL's complexity and a better ability to measure its components, it is now possible to move past HDL-C to more refined measures that better reflect HDL's role in coronary heart disease risk. Based on the accumulating evidence, incorporation of MS-HDL-P or HDL-P into the routine prediction of coronary heart disease risk should be considered," said senior author Dr. Jeremy Kark, professor of epidemiology at the Hebrew University of Jerusalem.

The study was published in the August 2016 issue of the journal Atherosclerosis.

Related Links:
Hebrew University of Jerusalem


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Manual Pipetting Aid
Pipette Controllers macro
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.